Chat with us, powered by LiveChat

Conjunctivitis Market (Disease Type - Bacterial Conjunctivitis, Viral Conjunctivitis, and Allergic Conjunctivitis): Global Industry Analysis, Trends, Size, Share and Forecasts to 2026

Conjunctivitis Market (Disease Type - Bacterial Conjunctivitis, Viral Conjunctivitis, and Allergic Conjunctivitis): Global Industry Analysis, Trends, Size, Share and Forecasts to 2026

Report Code: HC0037 Category: Healthcare & Medical Devices Published: August, 2017

A recent report published by Infinium Global Research on the conjunctivitis market provides an in-depth analysis of segments and sub-segments in the global as well as regional conjunctivitis market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional conjunctivitis market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global conjunctivitis market. According to the report, the global conjunctivitis market is projected to grow at a CAGR of 2.3% over the forecast period of 2020-2026.

 

Market Insight

Conjunctivitis is a common cause of eye redness that can affect people of any age, demographic, or socioeconomic status. It is a common eye condition that affects more than 2% of the global population annually. Viral, allergic, and bacterial conjunctivitis are the three most common types of conjunctivitis among the population. A wide variety of drugs and treatments are used to cure and relieve the symptoms of conjunctivitis. Bacterial conjunctivitis is treated with ophthalmic antibiotic eye drops or ointments, while, antihistamines are prescribed to treat allergic conjunctivitis. Viral conjunctivitis does not have any treatments, however, over-the-counter topical antihistamines and decongestants are used to relieve symptoms. The global conjunctivitis market is characterized by the presence of several treatments.

 

In the backdrop of the novel coronavirus (COVID-19) pandemic, the way the health and development communities are operating is rapidly changing. Routine out-patient visits and elective surgeries have been advised to be suspended by ophthalmic societies and by the government. Further, travel restrictions, reprioritization of health resources, and economic consequences are impacting the work of many organizations. Healthcare professionals need to attend to the patients requiring emergency ophthalmic interventions during this pandemic. All these factors together are anticipated to hamper the market over the short term. However, it is stated that the COVID-19 virus can cause ocular complications such as conjunctivitis, which may not be seen in the early stages of the disease. Though every patient in the present scenario could be a potential source of COVID-19, patients with conjunctivitis are being treated with greater fear, due to the possibility of having symptom of COVID-19 and the probable risk of transmission from tears of patients. This, in turn, is expected to boost the market growth for a shorter period.

 

The increasing prevalence of conjunctivitis patients across the globe and rising awareness among the population about pink eye disease are the key driving factors for the growth of the conjunctivitis market. The entry of new drugs and the increasing need for effective medication for viral conjunctivitis are the key considering factors for the growth of the conjunctivitis market. However, unfavorable government regulations and expiring drug patents have impeded the demand for branded drugs restraining the growth of this market. Furthermore, there are no approved drugs for the treatment of viral conjunctivitis, many companies are developing drugs that are expected to aid in the treatment of viral conjunctivitis and their effect will turn into a prominent opportunity to promote the growth of this market over the forecast period.

 

The global conjunctivitis market has been regionally segmented into the geographies of North America, Europe, Asia Pacific, and RoW. From a regional perspective, the North American region is expected to dominate the market, attributed to the growing number of conjunctivitis cases and the increasing demand for effective drugs. It is estimated that around 6 million new cases of viral conjunctivitis occur annually in the United States. Furthermore, the global market for conjunctivitis has largely benefitted from a wide range of affordable generic medications availability. Further, Asia Pacific will witness rapid growth in the forecast period owing to the rapidly growing population and growing awareness about medicines for treating conjunctivitis.

 

Segment Covered

The report on global conjunctivitis market covers segments such as disease type. On the basis of disease type, the sub-markets include bacterial conjunctivitis, viral conjunctivitis, and allergic conjunctivitis.

 

Companies Profiled:

The report provides profiles of the companies in the market such as Akorn Inc., Alcon Vision LLC, Allergan, Inc., Bausch & Lomb Incorporated, Sesen Bio, Inc., Griffin Discoveries BV, InSite Vision, Inc., Nicox SA, NovaBay Pharmaceuticals, Inc., and Ocular Therapeutix, Inc..

 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of conjunctivitis market. Moreover, the study highlights current market trends and provides forecast from 2020-2026. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


CHOOSE LICENCE TYPE

Please Choose One of them.

© 2024. Infinium Global Research LLP. All Rights Reserved.